Novartis halts ALS drug after phase 2 failure, extending R&D setbacks

Novartis has terminated its amyotrophic lateral sclerosis (ALS) program after the experimental therapy failed to meet its goals in a phase 2 study. The company did not disclose detailed efficacy or safety data in the announcement, but the miss was significant enough to halt further development. This marks another setback for a pipeline that has already seen several high-profile failures this year.

The decision underscores the difficulty of treating ALS, a neurodegenerative disease with few effective therapies. Novartis had positioned the drug as a potential breakthrough, but the phase 2 results did not support advancing to later trials. The company's R&D woes have been mounting, and this exit removes one of its more prominent mid-stage assets.

For patients and clinicians, the news is a reminder of the high attrition rate in ALS research. Novartis did not indicate whether it plans to pivot to other neurological indications. The broader biotech sector has struggled to replicate early ALS successes, and this program's failure adds to that pattern. No other details about the trial or next steps were provided in the source.